Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuromyelitis Spectrum Disorders.

Brian G Weinshenker1, Dean M Wingerchuk2

  • 1Department of Neurology, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|April 8, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunity Gone Viral: Subacute Cognitive Decline With Multifocal Brain Lesions in Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association study.

The Lancet. Neurology·2026
Same author

Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.

Journal of neurology·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Neuromyelitis optica spectrum disorder (NMOSD) understanding has advanced with aquaporin 4 IgG discovery. This autoantibody aids NMOSD diagnosis, differentiating it from multiple sclerosis (MS).

Area of Science:

  • Neuroimmunology
  • Autoimmune Disorders
  • Neurology

Background:

  • Neuromyelitis optica spectrum disorder (NMOSD) understanding has evolved significantly over the past century.
  • The discovery of aquaporin 4 IgG autoantibody in 2004 marked a turning point for NMOSD diagnosis and treatment.
  • NMOSD, while sharing similarities with multiple sclerosis (MS), has distinct clinical and radiologic features identified in the late 1990s.

Purpose of the Study:

  • To review the current understanding of NMOSD, focusing on clinical aspects, pathophysiology, and treatment.
  • To highlight the impact of autoantibody biomarkers on NMOSD diagnosis and differentiation from MS.
  • To discuss the classification of NMOSD based on targeted autoantibodies, specifically aquaporin 4 IgG and myelin oligodendrocyte glycoprotein IgG.

Main Methods:

Related Experiment Videos

  • Review of historical and recent scientific literature on NMOSD.
  • Analysis of diagnostic criteria evolution, incorporating autoantibody biomarkers.
  • Comparison of clinical and radiologic features of different NMOSD subtypes and MS.

Main Results:

  • Aquaporin 4 IgG-associated NMOSD is now recognized as an immune astrocytopathy affecting astrocytes.
  • Myelin oligodendrocyte glycoprotein IgG defines a distinct NMOSD syndrome with overlapping but unique features compared to aquaporin 4 IgG NMOSD and MS.
  • Updated diagnostic criteria enable accurate differentiation of NMOSD from MS.

Conclusions:

  • The identification of specific autoantibodies has transformed the understanding and management of NMOSD.
  • NMOSD is now classified into distinct entities based on targeted autoantibodies, guiding personalized treatment strategies.
  • Continued research into NMOSD pathophysiology and treatment is crucial for improving patient outcomes.